Is aspirin use associated with age-related macular degeneration? A meta-analysis

Journal of Clinical Pharmacy and Therapeutics

Volumn 40, Issue 2, 2015, Pages 144-154

  Li, L ^a   Li, W ^b   Chen, C Z ^a   Yi, Z H Z ^a   Zhou, Y Y ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b HUBEI CANCER HOSPITAL   (China)

Author keywords

age related macular degeneration; aspirin; meta analysis; neovascularization

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

AGE RELATED MACULAR DEGENERATION; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG USE; EXTERNAL VALIDITY; GENETIC HETEROGENEITY; GEOGRAPHIC ATROPHY; HUMAN; INTERNAL VALIDITY; META ANALYSIS; PATIENT RISK; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA NEOVASCULARIZATION; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; CHEMICALLY INDUCED; CLASSIFICATION; MACULAR DEGENERATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; HUMANS; MACULAR DEGENERATION; RISK ASSESSMENT;

EID: 84924203463     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12241     Document Type: Article

References (70)

1. Coleman HR, Chan CC, Ferris FL, et al,. Age-related macular degeneration. Lancet, 2008; 372: 1835-1845.
2. Klein R, Klein BE, Jensen SC, et al,. The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology, 1997; 104: 7-21.
3. Resnikoff S, Pascolini D, EtyaAle D, et al,. Global data on visual impairment in the year 2002. Bull World Health Organ, 2004; 82: 844-851.
4. Friedman DS, O'Colmain BJ, Munoz B, et al,. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol, 2004; 122: 564-572.
5. Snow KK, Seddon JM,. Do age-related macular degeneration and cardiovascular disease share common antecedents? Ophthalmic Epidemiol, 1999; 6: 125-143.
6. Erke MG, Bertelsen G, Peto T, et al,. Cardiovascular risk factors associated with age-related macular degeneration: the Tromso Study. Acta Ophthalmol, 2014; 92: 662-669.
7. Cougnard-Gregoire A, Delyfer MN, Korobelnik JF, et al,. Elevated high-density lipoprotein cholesterol and age-related macular degeneration: the Alienor study. PLoS ONE, 2014; 9: e90973.
8. Friedman E,. The role of the atherosclerotic process in the pathogenesis of age-related macular degeneration. Am J Ophthalmol, 2000; 130: 658-663.
9. Hageman GS, Luthert PJ, Victor CNH, et al,. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res, 2001; 20: 705-732.
10. Beatty S, Koh H, Phil M, et al,. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol, 2000; 45: 115-134.
11. Grunwald JE, Metelitsina TI, Dupont JC, et al,. Reduced foveolar choroidal blood flow in eyes with increasing AMD severity. Invest Ophthalmol Vis Sci, 2005; 46: 1033-1038.
12. Warner TD, Mitchell JA,. Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum? Proc Natl Acad Sci USA, 2002; 99: 13371-13373.
13. Baigent C, Blackwell L, Collins R, et al,. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet, 2009; 373: 1849-1860.
14. Roth GJ, Stanford N, Majerus PW,. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA, 1975; 72: 3073-3076.
15. Liew G, Mitchell P, Wong TY, et al,. The association of aspirin use with age-related macular degeneration. JAMA Intern Med, 2013; 173: 258-264.
16. de Jong PT, Chakravarthy U, Rahu M, et al,. Associations between aspirin use and aging macula disorder: the European Eye Study. Ophthalmology, 2012; 119: 112-118.
17. Cheung N, Tay WT, Cheung GC, et al,. Is aspirin intake associated with early age-related macular degeneration? The Singapore Indian Eye Study. Br J Ophthalmol, 2013; 97: 785-788.
18. Klein BE, Howard KP, Gangnon RE, et al,. Long-term use of aspirin and age-related macular degeneration. JAMA, 2012; 308: 2469-2478.
19. Christen WG, Glynn RJ, Chew EY, et al,. Low-dose aspirin and medical record-confirmed age-related macular degeneration in a randomized trial of women. Ophthalmology, 2009; 116: 2386-2392.
20. Wang JJ, Mitchell P, Smith W, et al,. Systemic use of anti-inflammatory medications and age-related maculopathy: the Blue Mountains Eye Study. Ophthalmic Epidemiol, 2003; 10: 37-48.
21. Christen WG, Glynn RJ, Ajani UA, et al,. Age-related maculopathy in a randomized trial of low-dose aspirin among US physicians. Arch Ophthalmol, 2001; 119: 1143-1149.
22. Kahawita SK, Casson RJ,. Aspirin use and early age-related macular degeneration: a meta-analysis. Can J Ophthalmol, 2014; 49: 35-39.
23. Ye J, Xu YF, He JJ, et al,. Association between aspirin use and age-related macular degeneration: a meta-analysis. Invest Ophthalmol Vis Sci, 2014; 55: 2687-2696.
24. Zhu W, Wu Y, Xu D, et al,. Aspirin use and risk of age-related macular degeneration: a meta-analysis. PLoS ONE, 2013; 8: e58821.
25. Moher D, Liberati A, Tetzlaff J, et al,. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med, 2009; 6: e1000097.
26. Klein R, Davis MD, Magli YL, et al,. The Wisconsin age-related maculopathy grading system. Ophthalmology, 1991; 98: 1128-1134.
27. Bird AC, Bressler NM, Bressler SB, et al,. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol, 1995; 39: 367-374.
28. Downs SH, Black N,. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health, 1998; 52: 377-384.
29. Samoocha D, Bruinvels DJ, Elbers NA, et al,. Effectiveness of web-based interventions on patient empowerment: a systematic review and meta-analysis. J Med Internet Res, 2010; 12: e23.
30. Begg CB, Mazumdar M,. Operating characteristics of a rank correlation test for publication bias. Biometrics, 1994; 50: 1088-1101.
31. Egger M, Davey SG, Schneider M, et al,. Bias in meta-analysis detected by a simple, graphical test. BMJ, 1997; 315: 629-634.
32. Higgins JP, Thompson SG, Deeks JJ, et al,. Measuring inconsistency in meta-analyses. BMJ, 2003; 327: 557-560.
33. Higgins JP, Thompson SG,. Quantifying heterogeneity in a meta-analysis. Stat Med, 2002; 21: 1539-1558.
34. Kaul S, Diamond GA,. Relationship of aspirin use with age-related macular degeneration: association or causation? comment on "The association of aspirin use with age-related macular degeneration". JAMA Intern Med, 2013; 173: 264-266.
35. Sobrin L, Seddon JM,. Regular aspirin use and risk of age-related macular degeneration. Am J Ophthalmol, 2013; 156: 213-217, e2.
36. Clemons TE, Milton RC, Klein R, et al,. Risk factors for the incidence of advanced age-related macular degeneration in the age-related eye disease study (AREDS) AREDS report no. 19. Ophthalmology, 2005; 112: 533-539.
37. Mascitelli L, Pezzetta F, Goldstein MR,. Aspirin, iron loss, and age-related macular degeneration. Med Hypotheses, 2010; 74: 754-755.
38. Hirvela H, Luukinen H, Laara E, et al,. Risk factors of age-related maculopathy in a population 70 years of age or older. Ophthalmology, 1996; 103: 871-877.
39. Age-Related Eye Disease Study Research Group. Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: age-related eye disease study report number 3. Ophthalmology, 2000; 107: 2224-2232.
40. Chew EY, Clemons T, SanGiovanni JP, et al,. The age-related eye disease study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology, 2012; 119: 2282-2289.
41. Keller DL,. Is 81-mg aspirin associated with age-related macular degeneration risk? JAMA Intern Med, 2013; 173: 1476.
42. Ramaswamy SG, Greenberg PB, Krzystolik MG,. Guideline-adherent aspirin use in individuals with age-related macular degeneration. J Am Geriatr Soc, 2013; 61: 1033-1034.
43. Wu Y, Zhu W, Li YH, et al,. Aspirin and age related macular degeneration: the possible relationship. Med Hypothesis Discov Innov Ophthalmol, 2013; 2: 59-68.
44. Hall NF, Martyn CN,. Could statins prevent age-related macular degeneration? Expert Opin Pharmacother, 2002; 3: 803-807.
45. Christen WG Jr, Antioxidants and eye disease. Am J Med, 1994; 97: 14S-17S; discussion 22S-28S.
46. Christen WG, Chew EY,. Does long-term aspirin use increase the risk of neovascular age-related macular degeneration? Expert Opin Drug Saf, 2014; 13: 421-429.
47. Christen WG,. Long-term aspirin use and neovascular age-related macular degeneration: association or causation? Evid Based Med, 2014; 19: e6.
48. Covinsky KE,. The incremental nature of clinical research: comment on "The association of aspirin use with age-related macular degeneration". JAMA Intern Med, 2013; 173: 266.
49. Hu X, Tang S,. Aspirin use and risk of macular degeneration. JAMA, 2013; 309: 1227.
50. Moon BG, Joe SG, Hwang JU, et al,. Prevalence and risk factors of early-stage age-related macular degeneration in patients examined at a health promotion center in Korea. J Korean Med Sci, 2012; 27: 537-541.
51. Wilson HL, Schwartz DM, Bhatt HR, et al,. Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration. Am J Ophthalmol, 2004; 137: 615-624.
52. Swanson MW, McGwin G Jr,. Anti-inflammatory drug use and age-related macular degeneration. Optom Vis Sci, 2008; 85: 947-950.
53. van Leeuwen R, Tomany SC, Wang JJ, et al,. Is medication use associated with the incidence of early age-related maculopathy? Pooled findings from 3 continents. Ophthalmology, 2004; 111: 1169-1175.
54. Gaynes BI,. Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among age-related macular degeneration patients. Am J Ophthalmol, 2004; 138: 1089; author reply 1090.
55. Tilanus MA, Vaandrager W, Cuypers MH, et al,. Relationship between anticoagulant medication and massive intraocular hemorrhage in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol, 2000; 238: 482-485.
56. Kiernan DF, Hariprasad SM, Rusu IM, et al,. Epidemiology of the association between anticoagulants and intraocular hemorrhage in patients with neovascular age-related macular degeneration. Retina, 2010; 30: 1573-1578.
57. Girgis RA, McKee HD,. Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration. Am J Ophthalmol, 2004; 138: 697; author reply 697-8.
58. Klein R, Klein BE, Jensen SC, et al,. Medication use and the 5-year incidence of early age-related maculopathy: the Beaver Dam Eye Study. Arch Ophthalmol, 2001; 119: 1354-1359.
59. Klein ML,. Macular degeneration: is aspirin a risk for progressive disease? JAMA, 1991; 266: 2279.
60. de Jong PT., Aspirin and age-related macular degeneration. Ophthalmology, 2010; 117: 1279-1280; author reply 1280.
61. Rudnicka AR, MacCallum PK, Whitelocke R, et al,. Circulating markers of arterial thrombosis and late-stage age-related macular degeneration: a case-control study. Eye (Lond), 2010; 24: 1199-1206.
62. Douglas IJ, Cook C, Chakravarthy U, et al,. A case-control study of drug risk factors for age-related macular degeneration. Ophthalmology, 2007; 114: 1164-1169.
63. DeAngelis MM, Lane AM, Shah CP, et al,. Extremely discordant sib-pair study design to determine risk factors for neovascular age-related macular degeneration. Arch Ophthalmol, 2004; 122: 575-580.
64. Blumenkranz MS, Russell SR, Robey MG, et al,. Risk factors in age-related maculopathy complicated by choroidal neovascularization. Ophthalmology, 1986; 93: 552-558.
65. Kuhli-Hattenbach C, Fischer IB, Schalnus R, et al,. Subretinal hemorrhages associated with age-related macular degeneration in patients receiving anticoagulation or antiplatelet therapy. Am J Ophthalmol, 2010; 149: 316-321, e1.
66. Miller JW,. Age-related macular degeneration revisited-piecing the puzzle: the LXIX Edward Jackson memorial lecture. Am J Ophthalmol, 2013; 155: 1-35, e13.
67. Holbrook AM, Pereira JA, Labiris R, et al,. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med, 2005; 165: 1095-1106.
68. Maloney SC, Fernandes BF, Castiglione E, et al,. Expression of cyclooxygenase-2 in choroidal neovascular membranes from age-related macular degeneration patients. Retina, 2009; 29: 176-180.
69. Battinelli EM, Markens BA, Italiano JE Jr,. Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis. Blood, 2011; 118: 1359-1369.
70. Goertz O, Ring A, Buschhaus B, et al,. Influence of anti-inflammatory and vasoactive drugs on microcirculation and angiogenesis after burn in mice. Burns, 2011; 37: 656-664.